2023-508819-23-00CompletedPhase 1
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia
Hutchmed Ltd.14 sites in 3 countries22 target enrollmentStarted: June 5, 2024Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 22
- Locations
- 14
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Clinical Trial Information
Scientific
Hutchmed Ltd.
Study Sites (14)
Loading locations...
Similar Trials
Completed
Phase 1
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
Recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants2024-512939-67-00Mindstate Design Labs Inc.68
Completed
Phase 1
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic functionUrticariaAllergic rhinitis2022-500774-34-00Noucor Health S.A.44
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors2023-504709-35-00Genentech Inc.44
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43